anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The effectiveness of paroxetine in the treatment of Generalized Anxiety Disorder (GAD) was demonstrated in two 8-week, multicenter, placebo-controlled studies (Studies 1 and 2) of adult outpatients with Generalized Anxiety Disorder (DSM-IV). 

Study 1 was an 8-week study comparing fixed paroxetine doses of 20 mg or 40 mg/day with placebo. Doses of 20 mg or 40 mg of paroxetine were both demonstrated to be significantly superior to placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score. There was not sufficient evidence in this study to suggest a greater benefit for the 40 mg/day dose compared to the 20 mg/day dose. 

Study 2 was a flexible-dose study comparing paroxetine (20 mg to 50 mg daily) and placebo. Paroxetine demonstrated statistically significant superiority over placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score. A third study, also flexible-dose comparing paroxetine (20 mg to 50 mg daily), did not demonstrate statistically significant superiority of paroxetine over placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score, the primary outcome. 

Subgroup analyses did not indicate differences in treatment outcomes as a function of race or gender. There were insufficient elderly patients to conduct subgroup analyses on the basis of age.

In a longer-term trial, 566 patients meeting DSM-IV criteria for Generalized Anxiety Disorder, who had responded during a single-blind, 8-week acute treatment phase with 20 to 50 mg/day of paroxetine, were randomized to continuation of paroxetine at their same dose, or to placebo, for up to 24 weeks of observation for relapse. Response during the single-blind phase was defined by having a decrease of ≥2 points compared to baseline on the CGI-Severity of Illness scale, to a score of ≤3. Relapse during the double-blind phase was defined as an increase of ≥2 points compared to baseline on the CGI-Severity of Illness scale to a score of ≥ 4, or withdrawal due to lack of efficacy. Patients receiving continued paroxetine experienced a significantly lower relapse rate over the subsequent 24 weeks compared to those receiving placebo.
The invention concerns a pharmaceutical form comprising a support material and at least a cell regulating factor and/or a cell proliferation promoter, preferably a growth factor. The invention is characterised in that the support material consists, for at least 90 wt. % of a composition based on methylidene malonate containing 0 to 10 wt. % of one or several methylidene malonate of formula (I) wherein: A and B independently represent a group (a) or (b) wherein R1 and R2 independently represent a C1-C6 linear or branched alkyl group, and n is an integer ranging between 1 and 5; 10 to 90 wt. %, preferably 50 to 90 wt. % of one or several methylidene malonate oligomer(s) having a molecular weight not more than 6000 and consisting of repeat units of formula (II) wherein A and B are such as defined above; 10 to 90 wt. %, preferably 10 to 50 wt. % of one or several methylidene malonate polymer(s) having a molecular weight more than 6000 and consisting of repeat units of formula (II). Said pharmaceutical form is useful for treating skin lesions.
Herein is provided a novel molecule and infusion solutions containing the molecule useful for the detection and imaging of EpCAM positive tumors as well as lymph nodes, such as, but not limited to, lower GI (i.e. colorectal) and upper GI (i.e. gastric and esophageal) cancers. The molecule is comprised of an antibody or antibody fragment capable of specifically targeting EpCAM conjugated to a NIR fluorescent dye. A preferred antibody fragment is VB5-845D and a preferred NIR fluorescent dye is IRDye 800CW. Aspects of the invention provide a method of intraoperative tumor visualization of EpCAM expressing primary tumors and lymph nodes.
The precise mechanism by which tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability, documented in in vitro experiments, to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. These experiments have shown that tiagabine binds to recognition sites associated with the GABA uptake carrier. It is thought that, by this action, tiagabine blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surfaces of post-synaptic cells. Inhibition of GABA uptake has been shown for synaptosomes, neuronal cell cultures, and glial cell cultures. In rat-derived hippocampal slices, tiagabine has been shown to prolong GABA-mediated inhibitory post-synaptic potentials. Tiagabine increases the amount of GABA available in the extracellular space of the globus pallidus, ventral palladum, and substantia nigra in rats at the ED50 and ED85 doses for inhibition of pentylenetetrazol (PTZ)-induced tonic seizures. This suggests that tiagabine prevents the propagation of neural impulses that contribute to seizures by a GABA-ergic action.

Tiagabine has shown efficacy in several animal models of seizures. It is effective against the tonic phase of subcutaneous PTZ-induced seizures in mice and rats, seizures induced by the proconvulsant DMCM in mice, audiogenic seizures in genetically epilepsy-prone rats (GEPR), and amygdala-kindled seizures in rats. Tiagabine has little efficacy against maximal electroshock seizures in rats and is only partially effective against subcutaneous PTZ-induced clonic seizures in mice, picrotoxin-induced tonic seizures in the mouse, bicuculline-induced seizures in the rat, and photic seizures in photosensitive baboons. Tiagabine produces a biphasic dose-response curve against PTZ- and DMCM-induced convulsions, with attenuated effectiveness at higher doses.

Based on in vitro binding studies, tiagabine does not significantly inhibit the uptake of dopamine, norepinephrine, serotonin, glutamate, or choline and shows little or no binding to dopamine D1 and D2, muscarinic, serotonin 5HT1A, 5HT2, and 5HT3, beta-1 and 2 adrenergic, alpha-1 and alpha-2 adrenergic, histamine H2 and H3, adenosine A1 and A2, opiate µ and K1, NMDA glutamate, and GABAA receptors at 100 µM. It also lacks significant affinity for sodium or calcium channels. Tiagabine binds to histamine H1, serotonin 5HT1B, benzodiazepine, and chloride channel receptors at concentrations 20 to 400 times those inhibiting the uptake of GABA.
Esophagectomy is a complex surgical procedure performed to treat various esophageal disorders. The surgery involves the removal of all or part of the esophagus and reconstruction using other parts of the gastrointestinal tract. Different surgical approaches and techniques have been developed, including open (transthoracic or transhiatal), minimally invasive (video-assisted thoracoscopic surgery or robotic-assisted), and hybrid approaches. These techniques may yield different clinical outcomes, and there is still ongoing debate regarding the optimal approach. Nevertheless, minimally invasive approaches, including robotic esophagectomy, are generally preferred given the lower morbidity. This prospective clinical registry aims to investigate outcomes of elective robotic transhiatal esophagectomy, the preferred approach at Northwestern Memorial Hospital, for adult patients undergoing this procedure. By collecting clinical and demographic data prospectively, we hope to identify factors that contribute to improved outcomes and guide future surgical practice.
PURPOSE: The use of inhaled bronchodilators is the mainstay of treatment for patients with chronic obstructive pulmonary disease (COPD). Although the soft mist inhaler (SMI) was developed to overcome the disadvantages of pressurized metered dose and drug powder inhalers, misuse during handling has been frequently observed in many studies. However, few studies have focused on SMI misuse among patients with COPD. Thus, we aimed to assess and identify the risk factors associated with SMI misuse among patients with COPD.
PATIENT AND METHODS: In this prospective, observational, cross-sectional study, we enrolled patients with COPD who were undergoing SMI treatment between January 2018 and March 2020. An advanced nurse practitioner assessed the participants' handling of the device by using a check list.
RESULTS: Among 159 participants, 136 (85.5%) reported inhaler misuse. Duration of COPD and COPD assessment test (CAT) scores were positively associated with inhaler misuse; adherence and education level were negatively associated with inhaler misuse. In the multivariable analysis, a low educational level (less than high school), high CAT score (≥ 10), and short duration of COPD (≤ 2 years) were identified as risk factors for SMI misuse.
CONCLUSION: SMI misuse remains common among patients with COPD. Therefore, clinicians should pay close attention to their patients using SMIs, especially in the early period after the diagnosis of COPD.
The invention is directed to medical device coatings, such as coated guidewires and catheters, containing a visualization moiety providing color to the coating in ambient or applied light. The coating allows for visual or machine inspection of coating properties such as uniformity of coverage. In some embodiments the coatings include the visualization moiety and an activated UV photogroup, which is used to provide covalent bonding in the coating. The visualization moiety can be in particulate form and entrained in the coating, or can be covalently bonded to the hydrophilic polymer backbone. In other embodiments the visualization moiety includes a stilbene chemical group. Exemplary coatings include a hydrophilic vinyl pyrrolidone polymer, which can provide lubricity to the device surface, along with the colored properties.
1357731 Pharmaceutical base composition ETHICHEM Ltd 19 April 1971 [12 Feb 1970 26 March 1970 (2)] 6784/70 14626/70 and 14627/70 Heading A5B [Also in Division C3] A free-flowing powder suitable for use as a disinfectant carrier or incorporation in a nappy rash ointment comprises (a) starch and optionally talc and (b) a buffer of pH 5.5-7.5 comprising a weak organic acid and a salt of a weak acid and a strong base. The weak organic acid may be acetic, succinic, citric, maleic or malonic acid. The salt of a weak acid may be disodium hydrogen orthophosphate or a sodium, potassium or calcium salt of a weak organic acid. The composition may also include an antiseptic, e.g. hexachlorophene, or benzalkonium chloride and a fatty acid ester, or amide or a fatty alcohol ether as a skin conditioner. It may be prepared by spray drying a liquid dispersion of the ingredients. The powder may be made into an ointment by compounding it with white soft paraffin wax. The ointment may also include a fatty acid, a fatty alcohol, e.g. cetyl alcohol, a fatty ester, e.g. isopropyl myristate, a wax, e.g. paraffin wax, water, a polyol and/or a colourant.
FIELD: biotechnology, medicine, veterinary science. SUBSTANCE: preparation has a carrier that is a sorbent and eubiotic cells immobilized on the indicated carrier. Eubiotic cells are used together with nutrient medium component at biotiter 10 8 -10 10  CFU/ml. Material exhibiting antacide property, developed meso- and macroporous structure and macropore volume 0.01 cm 3 /g, not less, is used as a sorbent at the following quantitative ratio of components, wt. -%: eubiotic cells at titer 10 8 -10 10  CFU/ml 1.0-50.0, and sorbent - the rest to 100%. Sorbent is a porous material based on aluminium oxide with hydrophilic-hydrophobic topochemistry of surface, for example, enterosorbent of type СУМС modified with carbon, or enterosorbent of type СИАЛ modified with organosilicon polymer. Bifido- or lactobacteria or their mixture are used as eubiotics. Complex preparation provides more effective prolonged curative-prophylaxis effect on organism of human or animals since it retains activity at all sites of gastroenteric tract. EFFECT: enhanced effectiveness of preparation. 5 cl, 2 tbl, 7 ex
Patients receive low dose belantamab mafodotin intravenously (IV) on day 1 of each cycle. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. All patients undergo a CT scan, a MRI scan, or a PET/CT scan during screening and patients with plasmacytoma (a MM tumor in bone or soft tissue) also undergo imaging scans on study. Patients undergo bone marrow aspirate and biopsy during screening and on study as well as collection of blood samples throughout the trial.
Parkinson's disease (PD) is a progressive neurogenerative movement disorder characterized by dopaminergic cell death within the substantia nigra pars compacta (SNpc) due to the aggregation-prone protein α-synuclein. Accumulation of α-synuclein is implicated in mitochondrial dysfunction and disruption of the autophagic turnover of mitochondria, or mitophagy, which is an essential quality control mechanism proposed to preserve mitochondrial fidelity in response to aging and stress. Yet, the precise relationship between α-synuclein accumulation, mitochondrial autophagy, and dopaminergic cell loss remains unresolved. Here, we determine the kinetics of α-synuclein overexpression and mitophagy using the pH-sensitive fluorescent mito-QC reporter. We find that overexpression of mutant A53T α-synuclein in either human SH-SY5Y cells or rat primary cortical neurons induces mitophagy. Moreover, the accumulation of mutant A53T α-synuclein in the SNpc of rats results in mitophagy dysregulation that precedes the onset of dopaminergic neurodegeneration. This study reveals a role for mutant A53T α-synuclein in inducing mitochondrial dysfunction, which may be an early event contributing to neurodegeneration.
As part of THPP+, the intervention will continue from the 6th month postnatal through 36 months postnatal and so will consist of an additional 30 months of lower intensity services that are unique to THPP+. The THPP+ will also include additional group sessions to be held every other month for a total of 18 over the intervention duration. The content will be a continuation of the previous THPP sessions with continuing emphasis on self-care as well as the baby's health and development.
FIELD: medicine, immunology. SUBSTANCE: invention relates to new preparations containing immunoreactive proteins that can be used for prophylaxis and/or treatment of septic shock. Invention relates to the product containing G-CSF or its pharmaceutically acceptable salt and TNF-binding protein or its pharmaceutically acceptable salt. This agent can be used for treatment and/or prophylaxis of septic shock. EFFECT: broadened arsenal of immunoreactive protein agents. 13 cl, 2 tbl, 1 ex
PROBLEM TO BE SOLVED: To obtain a high effective therapeutic agent against the infection with methicillin-resistant Staphylococcus aureus(MRSA) with side effects reduced. SOLUTION: This therapeutic agent contains at least one selected from lupulon of formula I, colupulon of formula II and adlupulon of formula III as an active ingredient. The compounds of formulas I, II and III belong to the β-acid as, an extraction component from hop (Humulus lupulus) known as a herb and used in beer brewing. In the treatment of MRSA infection, these compounds are systemically given in the form of a water-soluble injection or a water-soluble dripping solution. As an injection solution, these compounds can be prepared to a powder form for injection and an appropriate water-soluble excipient is added to dissolve in water and the solution is partitioned into vials or ampoules, freeze-dried and tightly sealed to give the objective preparation. In addition, it can be systemically dosed in the form of an aerosol of fine particles transnasally or transpulmonarily.  The deily dose is 0.05-2g/kg.adult.
PROBLEM TO BE SOLVED: To obtain a new antibody capable of recognizing a specific mol.wt. antibody existing on the surfaces of the endothelial cells of a tumor vessel and useful for tumor-treating medicines, tumor-diagnosing medicines, etc., singly, together with a chemical therapy medicine or in a state combined with a binding atom such as a radioactive isotope, etc. SOLUTION: This new monoclonal antibody is capable of recognizing an antibody having a mol.wt. of 40kD or 80kD and existing on the surfaces of the endothelial cells of a tumor vessel. The antibody is useful as a medicine or a diagnostic medicines especially for treating or diagnosing tumors singly, together with a chemical therapy medicine or in a state combined with a binding atom such as a radioactive isotope. The monoclonal antibody is obtained by immunizing an animal with cytoplasmic vesicles prepared from tumor vessel endothelial cells obtained from the KMT-17 solid tumor of a rat, isolating antibody-producing cells from the animal, fusing the isolated antibody-producing cells with myeloma cells, screening the obtained hybridoma and subsequently culturing the obtained monoclonal hybridoma to produce the antibody.
The adhesion of circulating tumor cells (CTCs) to the endothelial lumen and their extravasation to surrounding tissues are crucial in the seeding of metastases and remain the most complex events of the metastatic cascade to study. Integrins expressed on CTCs are major regulators of the extravasation process. This knowledge is primarily derived from animal models and biomimetic systems based on artificial endothelial layers, but these methods have ethical or technical limitations. We present a versatile microfluidic device to study cancer cell extravasation that mimics the endothelial barrier by using a porous membrane functionalized with DNA origami nanostructures (DONs) that display nanoscale patterns of adhesion peptides to circulating cancer cells. The device simulates physiological flow conditions and allows direct visualization of cell transmigration through microchannel pores using 3D confocal imaging. Using this system, we studied integrin-specific adhesion in the absence of other adhesive events. Specifically, we show that the transmigration ability of the metastatic cancer cell line MDA-MB-231 is influenced by the type, distance, and density of adhesion peptides present on the DONs. Furthermore, studies with mixed ligand systems indicate that integrins binding to RGD (arginine-glycine-aspartic acid) and IDS (isoleucine-aspartic acid-serine) did not synergistically enhance the extravasation process of MDA-MB-231 cells.
Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m\^2, bleomycin 10 U/m\^2, vinblastine 6 mg/m\^2, dacarbazine 375 mg/m\^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
This is a narrative review of the published evidence for bleeding management in critically ill patients in different clinical settings in the intensive care unit (ICU). We aimed to describe "The Ten Steps" approach to early goal-directed hemostatic therapy (EGDHT) using point-of-care testing (POCT), coagulation factor concentrates, and hemostatic drugs, according to the individual needs of each patient. We searched National Library of Medicine, MEDLINE for publications relevant to management of critical ill bleeding patients in different settings in the ICU. Bibliographies of included articles were also searched to identify additional relevant studies. English-language systematic reviews, meta-analyses, randomized trials, observational studies, and case reports were reviewed. Data related to study methodology, patient population, bleeding management strategy, and clinical outcomes were qualitatively evaluated. According to systematic reviews and meta-analyses, EGDHT guided by viscoelastic testing (VET) has been associated with a reduction in transfusion utilization, improved morbidity and outcome in patients with active bleeding. Furthermore, literature data showed an increased risk of severe adverse events and poor clinical outcomes with inappropriate prophylactic uses of blood components to correct altered conventional coagulation tests (CCTs). Finally, prospective, randomized, controlled trials point to the role of goal-directed fibrinogen substitution to reduce bleeding and the amount of red blood cell (RBC) transfusion with the potential to decrease mortality. In conclusion, severe acute bleeding management in the ICU is still a major challenge for intensive care physicians. The organized and sequential approach to the bleeding patient, guided by POCT allows for rapid and effective bleeding control, through the rational use of blood components and hemostatic drugs, since VET can identify specific coagulation disorders in real time, guiding hemostatic therapy with coagulation factor concentrates and hemostatic drugs with individual goals.
This is an open-label, Phase I study of the bioavailability and safety of Berg Pharma Molecule 31510 (BPM31510) in healthy subjects dosed 2 or 3 times daily for 4 days, after an initial cohort of 6 subjects receiving a single dose (pre-study cohort). The pre-study cohort subjects will receive 1600 mg as a single administration. Cohort 1 and Cohort 2 will consist of 10 patients each. Men and women over the age of 18, and in good general health, will undergo Screening and baseline evaluations up to 21 days prior to dosing. The cohorts may be enrolled sequentially. Subjects will be admitted to the clinic on Day 0.

All subjects will self-administer the all Day 1 doses of study drug under supervision of the clinic staff. In the pre-study cohort, subjects will be administered a single dose of 1600 mg. In Cohort 1, doses will be administered two times per day before the morning and evening meals with no less than 8 and no more than 10 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing. In Cohort 2 doses will be administered three times per day before meals, with no less than 4 and no more than 6 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing. Dosing will continue for an additional 4 days on an outpatient basis with the last study dose to be administered at the clinic on Day 5 (only morning dose is given on Day 5).

For the pre-study cohort, subjects will be administered a single dose of 1600 mg before breakfast. PK and PD sampling will be performed 30 minutes prior to dosing, and 0.5, 1, 2 and 4 hours later. Subjects will be evaluated for any untoward signs or symptoms and will be discharged. For cohorts 1 and 2, on Days 1, 2,and 5, pharmacokinetic (PK) and pharmacodynamics (PD) sampling will be performed 30 minutes prior to the first dose, and 0.5, 1, 2, and 4 hours after the first dose at all visits for BID and TID (with an additional PK draw on Day 1 at 0.5, 1, 2, and 4 after the second dose of TID subjects only). Urine for PK/PD will be collected pre-dose on Day 1, Day 2, and Day 5. At all visits (on Days 1, 2,and at the final dose on Day5), samples will be collected for chemistry, CBC, INR, PT, PTT, cholesterol, LDL, and HDL, and vitamin K level. Blood samples for PK/PD will be collected 30 minutes prior to the last dose (AM) on Day 5 and also at 0.5, 1, 2, and 4 hours after dosing. Lab samples (chemistry, etc.), as above will also be drawn at the time of the first PK/PD draw on Day 5.

A phone interview will be conducted no fewer than 25 days and no more than 35 days after the last dose on Day 5 to collect information on concomitant medications and adverse events (AEs).